Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy

Abstract

Among patients initiating pregabalin or gabapentin, there were no significant differences between the drugs in the pre- to post-index changes in all-cause total healthcare costs, despite the increase in prescription costs for pregabalin.

Cost comparison of drug–drug and drug–condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine

“…Clinical characteristics were measured during the 12 months before the index date, based on inpatient medical, outpatient medical, and outpatient pharmaceutical claims data using ICD-9-CM codes, CPT codes, Healthcare Common Procedure Coding System codes, and National Drug Codes, as appropriate. [20][21][22] Statistical analyses. Univariate, bivariate, and multivariable statistical analyses were used to address this study's objectives.…”

Pain-related pharmacotherapy, healthcare resource use and costs in spinal cord injury patients prescribed pregabalin

“…Although this finding is puzzling, it conceivably represents the natural progression of comorbidities including sleep impairment in SCI patients rather than being related to pregabalin treatment. Compliance with pregabalin in SCI patients (MPR, 87% and PDC, 78%) was higher than compliance rates for pregabalin reported in patients with other chronic pain conditions, including diabetic neuropathy (DPN), PDC 47%; 15 and fibromyalgia (FM), MPR, 79%, 16 and PDC between 52 and 59%. 17,18 Persistence with Initial use of pregabalin in SCI patients M Gore et al pregabalin therapy was also higher (median ¼ 141.5 days, mean ¼ 164 days) than reported in patients with DPN (mean between 87 days and 113 days) 15,19 and FM (median 90 days).…”

“…Compliance with pregabalin in SCI patients (MPR, 87% and PDC, 78%) was higher than compliance rates for pregabalin reported in patients with other chronic pain conditions, including diabetic neuropathy (DPN), PDC 47%; 15 and fibromyalgia (FM), MPR, 79%, 16 and PDC between 52 and 59%. 17,18 Persistence with Initial use of pregabalin in SCI patients M Gore et al pregabalin therapy was also higher (median ¼ 141.5 days, mean ¼ 164 days) than reported in patients with DPN (mean between 87 days and 113 days) 15,19 and FM (median 90 days). 18 Such adherence to therapy may be considered a combined surrogate for efficacy and tolerability, as patients who continue on a therapy generally do so because it is effective and well tolerated, or conversely, the drug is not being discontinued for adverse events or lack of efficacy.…”

Identification of Patients with Painful Diabetic Peripheral Neuropathy Who Have a Favorable Cost Profile with Pregabalin Treatment

“…Propensity scores were generated using all available baseline demographic and patient characteristics using a logistic regression model to predict the probability of treatment that included age at index, gender, Charlson Comorbidity Index (CCI) score, pre‐index hypertension, pre‐index mental disorders (including depression, bipolar disorder, anxiety, generalized anxiety disorder, panic disorder, or posttraumatic stress disorder), the number of pre‐index opioid analgesic prescriptions, and pre‐index total healthcare costs. The variables were selected by reviewing a list of available variables in claims data and those used in previous studies as key predictors of healthcare costs . Groups were matched pairwise using 1:1 matching of an observation in the smaller treatment group with the observation from the larger group with the nearest predictive probability.…”